Aclaris Therapeutics (ACRS) Receivables (2017 - 2025)
Aclaris Therapeutics (ACRS) recorded quarterly Receivables of $194000.0 in Q2 2025, down 22.4% quarter-over-quarter from $250000.0 in Q1 2025, and down 72.29% on a YoY basis from $700000.0 in Q2 2024.
Aclaris Therapeutics (ACRS) Receivables (2017 - 2025) Analysis & Trends
Aclaris Therapeutics' Receivables history runs 9 years deep, the most recent figure standing at $194000.0 for Q2 2025.
- In Q2 2025, Receivables fell 72.29% year-over-year to $194000.0; the TTM figure through Jun 2025 stood at $194000.0 (down 72.29% YoY), while the FY2024 annual figure was $318000.0, up 6.71% from the prior year.
- Receivables was $194000.0 for Q2 2025 at Aclaris Therapeutics, down from $250000.0 in the prior quarter.
- In the past five years, Receivables ranged from a high of $939000.0 in Q2 2021 to a low of $194000.0 in Q2 2025.
- Historically, Receivables has averaged $529111.1 across 5 years, with a median of $540500.0 in 2022.
- The sharpest annual moves came in 2024 and 2025: Receivables surged 62.41% in 2024, then sank 72.29% in 2025.
- A 5-year view of Receivables shows it stood at $647000.0 in 2021, then declined by 25.19% to $484000.0 in 2022, then sank by 38.43% to $298000.0 in 2023, then advanced by 6.71% to $318000.0 in 2024, then slumped by 38.99% to $194000.0 in 2025.
- The last three Receivables figures came in at $194000.0 (Q2 2025), $250000.0 (Q1 2025), and $318000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 13.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 2.00 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Aclaris Therapeutics | 580.93 Mn | 580.93 Mn | 1.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 194,000.00 |
| Mar 31, 2025 | 250,000.00 |
| Dec 31, 2024 | 318,000.00 |
| Sep 30, 2024 | 343,000.00 |
| Jun 30, 2024 | 700,000.00 |
| Mar 31, 2024 | 373,000.00 |
| Dec 31, 2023 | 298,000.00 |
| Sep 30, 2023 | 346,000.00 |
| Jun 30, 2023 | 431,000.00 |
| Mar 31, 2023 | 686,000.00 |
| Dec 31, 2022 | 484,000.00 |
| Sep 30, 2022 | 597,000.00 |
| Jun 30, 2022 | 637,000.00 |
| Mar 31, 2022 | 633,000.00 |
| Dec 31, 2021 | 647,000.00 |
| Sep 30, 2021 | 811,000.00 |
| Jun 30, 2021 | 939,000.00 |
| Mar 31, 2021 | 837,000.00 |
| Dec 31, 2020 | 1.07 Mn |
| Sep 30, 2020 | 1.19 Mn |